Viking Therapeutics stock surges 12% amid Novo Nordisk trial woes

Viking shares tumble after Merck inks deal with Hansoh Pharma

Viking shares declined by 5.5% following a licensing agreement between Hansoh Pharma and Merck regarding the development of a new metabolic disorder treatment.

Nvidia, Roblox, Sherwin-Williams rise premarket; Trump Media falls

US stock futures rise amid a significant week with elections and Fed meetings; Nvidia, Roblox, and Sherwin-Williams gain, while Trump Media, Marriott, and Phunware decline.

Earnings call: Viking Therapeutics Q3 financials and clinical updates

Earnings call: Viking Therapeutics Q3 financials and clinical updates

Viking Therapeutics reported Q3 2024 results, showing a net loss of $24.9M, strong cash reserves, and advancements in clinical trials, particularly VK2735 and VK2809.

Viking therapeutics director sells shares worth over $715,000

Viking Therapeutics' director sold shares for $715,000 amid promising drug development and notable market performance, attracting investor interest and analyst positivity ahead of earnings.

Viking therapeutics CEO sells over $15m in company stock

Brian Lian, CEO of Viking Therapeutics, sold over $15 million in shares but retains significant holdings; the company reports strong trial results and financial stability.